1. Home
  2. LGVN

as of 12-15-2025 1:32pm EST

$0.57
$0.03
-5.72%
Stocks Health Care Medicinal Chemicals and Botanical Products Nasdaq

Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.

Chart Type:
Time Range:
Founded: 2014 Country:
United States
United States
Employees: N/A City: MIAMI
Market Cap: 17.6M IPO Year: 2021
Target Price: $6.50 AVG Volume (30 days): 408.1K
Analyst Decision: Strong Buy Number of Analysts: 2
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -1.35 EPS Growth: N/A
52 Week Low/High: $0.58 - $2.24 Next Earning Date: 11-04-2025
Revenue: $1,437,000 Revenue Growth: -22.41%
Revenue Growth (this year): -51.96% Revenue Growth (next year): -38.27%

AI-Powered LGVN Daily Prediction

Machine learning model trained on 25+ technical indicators

Updated 20 hours ago

AI Recommendation

hold
Model Accuracy: 71.52%
71.52%
Confidence

Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.

Share on Social Networks: